Contribution of Anoctamins to Cell Survival and Cell Death by Kunzelmann, Karl et al.
cancers
Review
Contribution of Anoctamins to Cell Survival and
Cell Death
Karl Kunzelmann * , Jiraporn Ousingsawat, Roberta Benedetto, Ines Cabrita and
Rainer Schreiber
Institut für Physiologie, Universität Regensburg, Universitätsstraße 31, D-93053 Regensburg, Germany;
Jiraporn.Ousingsawat@vkl.uni-regensburg.de (J.O.); Roberta.Benedetto@vkl.uni-regensburg.de (R.B.);
Ines.Cabrita@vkl.uni-regensburg.de (I.C.); Rainer.Schreiber@vkl.uni-regensburg.de (R.S.)
* Correspondence: Karl.kunzelmann@ur.de; Tel.: +49-941-943-4302; Fax: +49-941-943-4315
Received: 19 February 2019; Accepted: 16 March 2019; Published: 19 March 2019


Abstract: Before anoctamins (TMEM16 proteins) were identified as a family of Ca2+-activated chloride
channels and phospholipid scramblases, the founding member anoctamin 1 (ANO1, TMEM16A) was
known as DOG1, a marker protein for gastrointestinal stromal tumors (GIST). Meanwhile, ANO1
has been examined in more detail, and the role of ANO1 in cell proliferation and the development
of different types of malignomas is now well established. While ANO5, ANO7, and ANO9 may
also be relevant for growth of cancers, evidence has been provided for a role of ANO6 (TMEM16F)
in regulated cell death. The cellular mechanisms by which anoctamins control cell proliferation
and cell death, respectively, are just emerging; however, the pronounced effects of anoctamins
on intracellular Ca2+ levels are likely to play a significant role. Recent results suggest that some
anoctamins control membrane exocytosis by setting Ca2+i levels near the plasma membrane, and/or
by controlling the intracellular Cl− concentration. Exocytosis and increased membrane trafficking
induced by ANO1 and ANO6 may enhance membrane expression of other chloride channels, such
as CFTR and volume activated chloride channels (VRAC). Notably, ANO6-induced phospholipid
scrambling with exposure of phosphatidylserine is pivotal for the sheddase function of disintegrin
and metalloproteinase (ADAM). This may support cell death and tumorigenic activity of IL-6 by
inducing IL-6 trans-signaling. The reported anticancer effects of the anthelminthic drug niclosamide
are probably related to the potent inhibitory effect on ANO1, apart from inducing cell cycle arrest
through the Let-7d/CDC34 axis. On the contrary, pronounced activation of ANO6 due to a large
increase in intracellular calcium, activation of phospholipase A2 or lipid peroxidation, can lead to
ferroptotic death of cancer cells. It therefore appears reasonable to search for both inhibitors and
potent activators of TMEM16 in order to interfere with cancer growth and metastasis.
Keywords: anoctamin; ANO1; ANO6; TMEM16A; TMEM16F; cancer; proliferation; apoptosis; Ca2+
signaling; inflammation
1. Introduction
Cl− currents activated by an increase in intracellular Ca2+ (CaCC) have been known for more
than 40 years. The human homologue of Drosophila tweety and the bestrophin family of channels
were shown to operate as Ca2+ activated Cl− channels (reviewed in [1–3]). However, they behave
differently from the “classical” receptor-operated CaCC, identified 11 years ago as anoctamin 1
(ANO1; TMEM16A) [4–6]. ANO1 is particularly expressed in acinar cells of secretory glands and is
regulated by CLCA1 [7,8]. Apart from glands, CaCCs have long been known to be present primarily
in proliferating cells in culture and various types of cancer cells [9–11]. After identification of ANO1
as Ca2+ activated Cl− channel, it became clear that the protein is identical to DOG1, a significant and
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reliable tumor marker in gastrointestinal stromal tumors (GIST) and head and neck cancers [12–14]
(Table 1). Meanwhile, ANO1 has been found in a number of different malignant tumors. Apart
from ANO1, other members of the anoctamin family were also correlated with cell proliferation and
cancer development, like ANO5 (TMEM16E), ANO7 (TMEM16G) and ANO9 (TMEM16J) (Table 1).
Anoctamins could have tumor-specific functions, or may support cell proliferation and possible
development towards malignancy in any cell-type. The latter assumption is supported by the fact
that ANO1 is present in many different types of proliferating cells and tumor tissues [15] (Table 1).
Notably, the ANO1-knockout mouse is hypotrophic when compared to wild type littermates [16].
ANO1 and its role in proliferation and cancer development has been reported repeatedly, but we are
still far from any comprehensive understanding. Compared to Ano1, much less is known for other
anoctamin paralogues regarding their potential role in proliferation and tumor development (Table 1).
Moreover, some anoctamins, like ANO6, may even promote cell death, rather than growth.
Table 1. Anoctamins in Cancer and Proliferation.
Anoctamin Paralogue References
Anoctamin 1, TMEM16A













Salivary gland cancer [67]
Chondroblastoma [68]












2. Anoctamins and Their Cellular Localization
Anoctamins form a family of Ca2+-activated proteins, consisting of phospholipid scramblases
and ion channels [90,91]. The 10 proteins (ANO1-10; TMEM16A-K) are broadly expressed in epithelial
and non-epithelia tissues [15]. ANO1 appears to operate as a relatively selective anion channel [92],
while ANO6 is a phospholipid scramblase, i.e., it moves phosphatidylserine from the inner to the outer
plasma membrane leaflet, when activated by a large increase in intracellular Ca2+ [93,94]. However,
ANO6 is also permeable for chloride ions [95–97]. Previous work suggests that it becomes increasingly
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nonselective with increasing concentrations of intracellular free Ca2+ [98]. Although it is now clear
that most anoctamins operate as phospholipid scramblases [99–101], our earlier work may suggest
that all anoctamins also conduct ions, when co-expressed with purinergic receptors and activated by
stimulation with ATP [102]. A subsequent study on the role of ANO5 for muscle repair presented
strong evidence that ANO5 is a scramblase and conducts ions as well [103].
It is not entirely clear to what extent anoctamins operate as channels/scramblases in the
apical plasma membrane of polarized cells, and what fraction of the protein resides in intracellular
membranous compartments, or in the basolateral plasma membrane. For example, ANO1 is apical
in pancreas, salivary gland, and airways, but it is basolateral in mouse colonic epithelia [104–107].
Cellular location of ANO1 may therefore depend on the cell type, and maybe on the cell function and
differentiation. For example, ANO5 is mostly found intracellularly, but it can be also detected in the
plasma membrane where it produces a non-selective whole cell current [15,102]. Endogenous and
overexpressed ANO10 is typically intracellular, and co-localizes with acetylated tubulin [108–110].
However, expression and localization appears tissue dependent and may dependent on the cell cycle.
For example, endogenous ANO10 in rapidly proliferating Fisher Rat Thyroid (FTR) cells is mostly
intracellular and appears upregulated during mitosis [108] (Figure 1). Once FRT cells form a dense
monolayer and stop proliferating in serum free media, some ANO10 moves into the cell membrane and
co-localizes with the centrioles [108] (Figure 1A). Non-proliferating cells on permeable supports and
in the absence of serum seem to lower expression of ANO10, which is now preferentially expressed
close to the centriole and probably in the primary cilium (Figure 1). Expression in the primary cilium
has also been observed for ANO1 and ANO6 in renal and retinal pigment epithelial cells [111–113].
We may therefore hypothesize a dynamic regulation of expression and localization of anoctamins,
depending on proliferation and on the cell cycle (Figure 1B). As discussed below, upregulation of
ANO1 is correlated with enhanced proliferation, e.g., in polycystic kidney disease, in many rapidly
growing cell lines, as well as in different types of tumors [73,114] (Table 1).
Figure 1. Proliferation-dependent expression of ANO10 in FRT cells. (A) FRT cells were grown
in FCS-containing media at 70% density (Proliferating), as confluent monolayer in FCS-free media
(Monolayer), or as polarized monolayer on permeable supports and in FCS-free media (Polarized).
Expression of endogenous ANO10 (green fluorescence) was intracellular in dividing cells (Proliferating),
but was detected in the plasma membrane and in the primary cilium in densely grown cells (Monolayer).
ANO10 was more prominent in plasma membrane and primary cilium in polarized cells (Polarized).
For further details and references, see main text. (B) Hypothetical model proposing variable cellular
locations of ANO10 depending on cell proliferation or cell polarization. ANO10 is found primarily
intracellularly, but is also in the plasma membrane during cell cycle. Reduced expression of ANO10
and translocation into the primary cilium is observed once cells move into G0. Bar, 20 µm [108].
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3. How Is ANO1 Upregulated during Cell Proliferation and Cancer Development?
Most studies on ANO1 have been performed on cultured cells, particularly in ANO1
overexpressing cells. Under these conditions, ANO1 currents are generally of large size and may
show some properties that are different to currents expressed endogenously [95,115]. Although
ANO1 is widely expressed and particularly abundant in epithelial cells [15,90,91], we observed that
non-proliferating epithelial cells in culture or freshly isolated (non-cultured) cells from airways,
kidney and intestine show very little Ca2+ activated Cl− currents [116–118]. However, ANO1
currents are quickly upregulated once cells have been isolated from the tissue and are maintained
in serum-containing media under proliferating conditions. Upregulation of ANO1-currents can be
reversed by growing the cells on permeable supports and removing the serum so that cells stop
proliferating [11,106,116,117,119,120]. Thus, removing the cells from their physiological environment,
cellular reorganization and pro-mitotic stimulation may all contribute to upregulation of ANO1.
Moreover, transcriptional stimulation via the IL4/IL13-Jack-STAT3-STAT6 axis, steroid hormones such
as testosterone, activation of histone deacetylase (HDCA), promotor hypo- methylation, as well as
downregulation of inhibitory micro-RNAs have been shown to upregulate ANO1 expression (reviewed
in [73,74,76,121,122] (Figure 2).
Figure 2. Upregulation and redistribution of ANO1 during proliferation and cancer. Scheme
summarizing reported factors and signaling pathways that lead to upregulation of expression of
ANO1 and cellular redistribution during proliferation and cancer growth (Table 1). For further details
and references, see main text.
4. ANO1, Cell Proliferation and Tumor Growth: How Does It Work?
ANO1 was found to increase proliferation in many different tissues [14,26,30,71,72,75,114,123–125]
(Table 1). Apart from increasing proliferation, additional pro-apoptotic effects of ANO1 have also been
reported, based on studies using ANO1-inhibitors. It should be noted, however, that ANO1-inhibitors
might exert non-specific effects, when used at higher concentrations. In contrast, inhibition of
proliferation by knockout of ANO1-expression or inhibition of ANO1 using low concentrations of
ANO1 inhibitors have been shown in a number of studies [73,126,127]. This can also be demonstrated
in experiments using nanomolar concentrations of the recently identified potent ANO1 inhibitor
niclosamide, which however, has a number of additional anti-cancer effects (c.f. below) [128].
Nevertheless, other ANO1-inhibitors also blocked cell proliferation and cancer growth [30,72,127,129].
Niclosamide is a FDA-approved drug and was shown to inhibit Notch signaling [130], a
pathway that is well known to participate in tumorigenesis [131]. In a number of reports, additional
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antineoplastic mechanisms of niclosamide have been described. Thus, niclosamide was shown to
inhibit nuclear factor kappa B (NF-κB), Wnt/ß-catenin signaling, the IL-6-JAK1-STAT3-pathway,
GSK-3 and more [132–140]. A recent paper suggests cell cycle arrest by niclosamide, through
activation of the Let-7d/CDC34 axis [41]. Notably, blockade of notch signaling inhibits goblet cell
metaplasia in asthmatic mice, which could be part of the mechanism how niclosamide inhibits mucus
production [128,141,142]. Moreover, mucus production is also inhibited by other ANO1 inhibitors,
such as niflumic acid (NFA) and CaCCinhAO1, or in ANO1 knockout mice [107,143,144]. Although
the antiproliferative effects of niclosamide correspond well to its inhibitory effect on ANO1, this
relationship is not well recognized. Niclosamide has been used in a number of preclinical studies and
even in clinical trials with prostate and colorectal cancer patients [135,137,145–149]. Taken together,
the multiple anti-cancer effects described for the ANO1-inhibitor niclosamide, may correspond to the
wide range of pro-cancerous mechanisms by ANO1 (Figure 3).
Figure 3. Mechanisms for ANO1-induced cell proliferation and cancer development. Scheme
summarizing reported mechanisms for ANO1-induced cell proliferation and development of cancer.
All pathways are inhibited by niclosamide and other inhibitors of anoctamins (Table 1). For further
details and references, see main text.
5. ANO5, 6, 7, and 9 in Cancer and Cell Proliferation
Other members of the anoctamin family were also associated with cell proliferation,
embryogenesis and cancer growth. ANO5 (TMEM16E) is now known for its role in myoblast
proliferation and muscle repair [80,103], while gain of function mutations of ANO5 cause
gnathodiaphyseal dysplasia [150]. In a collaborative effort, we identified an essential role of ANO6
for embryogenesis [151]. Similar to ANO5 also ANO6 was also reported to control myoblast
proliferation [80]. ANO7 (TMEM16G, NGEP) is a marker for prostate cancer [85,86]. For ANO9
(TMEM16J) an inverse correlation of expression and progression of colorectal cancer was described [89],
while it may also promote pancreatic cancer [88]. Interestingly, enhanced phospho-Erk1,2 activity was
correlated with the cellular effects of ANO1, 6, and 9, but a possible common mechanism remains
obscure [30,80,88].
6. Anoctamins Control Intracellular Ca2+ Levels
Growth hormone receptors signal via Ras/Raf/Erk1,2, PI3K/Akt, and DAG/IP3 [152], while
intracellular Ca2+ signals are essential regulators of cell proliferation [153]. We showed that anoctamins
control compartmentalized Ca2+ signals ([Ca2+]i), and therefore proposed this as a major mechanism
by which ANO1, and possibly other anoctamins, affect cell proliferation and a number of other
cellular properties [108,110,154,155]. It is important to note that ANO1 is homologous to yeast Ist2,
known to tether the peripheral cortical endoplasmic reticulum (ER) to the plasma membrane [156].
Gamper and collaborators convincingly showed that the relatively low Ca2+ sensitivity of ANO1 at
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(physiological) negative membrane voltages, requires this mechanism in order to concentrate Ca2+ near
the plasma membrane and in close proximity of ANO1 [157,158]. ER-localized inositol trisphosphate
receptors interact with ANO1 and tether the ER to ANO1 containing plasma membranes [157].
Moreover, IP3-induced Ca2+ store release is augmented by ANO1 [110]. Anoctamin-controlled Ca2+
compartments could be relevant for expression and activation of Erk1,2 [30,159]. Transient rise in
intracellular Ca2+ followed by sustained activation of the Ras/Raf/Erk pathway is a central aspect of
cell proliferation in many systems [154,160–162].
Although detailed mechanisms are currently not fully understood, it is clear that also other
anoctamins affect [Ca2+]i, i.e., basal [Ca2+]i as well as receptor mediated Ca2+ signals depend
on expression of anoctamins [110]. Apart from compartmentalization, protein interaction [163]
and membrane depolarization, anoctamins may also contribute to cell proliferation and cell
growth by operating as counter-ion channels. Counter ion movement of K+ or Cl− over the
ER membrane is necessary for charge compensation to allow for efficient Ca2+ transport out
of the ER via release channels, and for re-uptake of Ca2+ into the ER by the sarcoplasmic
endoplasmic reticulum Ca2+-ATPase (SERCA) [164,165]. Given the Ca2+ permeability of some
anoctamins, they may also serve as plasma membrane localized Ca2+ channels [90,166–168] or ER
Ca2+ leakage channels [103,110,154,169–171]. Disturbed intracellular Ca2+ signals with changes of
cellular properties are detectable in naïve tissues and primary cells from mice with knockout of
anoctamins [107,108,110,155,172–174] (Figure 4).
Figure 4. Compartmentalized Ca2+ signaling by anoctamins. Scheme illustrating the effects of
anoctamins on Ca2+ signaling. ANO1 tethers ER Ca2+ stores close to the plasma membrane, which
leads to improved ATP-induced apical Ca2+ signaling. Activation of both ANO1 and ANO6 induce
plasma membrane depolarization, supporting release of Ca2+ from ER stores via inositol trisphosphate
receptors (IP3R) and ryanodine receptors (RyR). In addition, Ca2+ store content was found to be
enhanced by ANO1. ANO6 is permeable for Ca2+ and therefore supports Ca2+ entry. ANO4 localized
in the ER interacts with Orai1 [110]. For further details and references, see main text.
7. The Role of Anoctamins in Controlling Intracellular Cl− Concentration, Exocytosis, Organ
Growth and Microvesicular Signaling
Recent reports suggest additional mechanisms whereby anoctamins may augment proliferation
and cell growth. He and coworkers proposed an interesting concept in which ANO1 controls
cytoplasmic Cl− levels that affect phosphoinositide levels in the inner plasma membrane leaflet,
such as PtdIns(4,5)P2 in membrane microdomains [175]. Although the proposed concept requires
further validation, it could contribute to attenuated purinergic Ca2+ signals found in tissues isolated
from conditional ANO1 knockout animals or in ANO1 knockout cells (c.f. above). Similar to He
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et al., we also detected shortened motile cilia in the respiratory epithelium of ANO1-knockout
mice, as well as a reduced length of non-motile primary cilia in renal collecting ducts of ANO1
knockout mice. While motile cilia from wt animals measured 6.1 ± 0.4 µm, those from animals with
a ANO1-knockout in ciliated epithelial cells had a length of only 3.6 ± 0.4 µm (n = 7). Finally, the
data by Ruppersburg and Hartzell convincingly demonstrate the importance of ANO1 for primary
ciliogenesis [111]. siRNA-suppression of ANO6 expression and expression of other anoctamins
suggested a contribution to basal Cl− conductance [102]. In contrast, overexpression of ANO1 and
ANO6 enhanced basal Cl− conductance when analyzed at 37 ◦C [95]. In contrast to He et al., we found
that ongoing activation of ANO1 (or ANO6) by either ionomycin or purinergic stimulation increased
intracellular Cl− concentrations in HEK293 and HeLa cells [102]. Nevertheless the proposed concept
that intracellular Cl− levels determine vesicular endocytosis/exocytosis, control apical membrane
delivery and morphogenesis [175], is interesting and corresponds well to the role of ANO1 in exocytosis
and normal renal development detected in recent studies [107,175–177] (Figure 5). It is also noteworthy
that intracellular Cl− regulation by ANO1 has been shown to participate in transcription of human
epidermal growth factor receptor 2, which mediates PI3K/AKT/mTOR and JAK/STAT3 signaling
pathways [52].
Figure 5. Potential action of anoctamins on exocytosis, growth and microvesicular signaling. ANO1
and ANO6 determine the extent of membrane protrusions and membrane blebbing in macrophages
and other cell types, and support cell migration, diapedesis and cancer metastasis. Exosome release
and paracrine signaling by epithelial cells is probably anoctamin-dependent. Support of membrane
unfolding, cell swelling and subsequent activation of VRAC could be a general property of anoctamins.
Mucus secretion and release of inflammatory mediators such as autacoids and cytokines was shown to
be ANO1-dependent. Exocytosis leads to enhanced expression of membrane proteins, cell growth, and
extensions such as motile cilia and the primary cilium, as proposed for ANO1. For further details and
references, see main text.
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We observed that animals lacking expression of ANO1 in epithelial cells of airways and intestine
accumulate mucus in club (Clara) and goblet cells [107]. We found that ANO1 is essential for secretion
of mucus, probably by controlling mucus release from club/goblet cells, and by controlling release of
prosecretory cytokines from ciliated cells [107]. IL-13-induced production and secretion of Muc5AC
was inhibited by the ANO1 blocker and antiproliferative/anticancer drug, niclosamide. Along
the same line, release of IL-8 induced by lipopolysaccharide (LPS) was significantly reduced by
knockdown of ANO1. A recent paper by Hilgemann and colleagues demonstrates massive membrane
expansion with activation of ANO6, with subsequent membrane shedding [178]. These results are
reminiscent to our earlier observations of ANO6-depending blebbing and membrane shedding in
macrophages [98]. Taken together, there is now evidence that anoctamins, particularly ANO1 and
ANO6, control endolysosomal trafficking [98,107,108,175,179,180], membrane exocytosis, increase in
membrane surface area and insertion of proteins into the plasma membrane [155,176,181] (Figure 5).
As outlined above, ANO1 and ANO6 control [Ca2+]i, which is an essential regulator of exocytosis.
Thus compartmentalized [Ca2+]i close to the plasma membrane is required for docking of exocytic
vesicles and granules, respectively. This process requires the so-called Munc13 proteins and the soluble
N-ethylmaleimide-sensitive factor-attachment protein receptor machinery [182,183].
Anoctamins were shown to have additional impact on cancer related events that
involve plasma membrane function. Both ANO1 and ANO6 support cell migration and
metastasis [14,26,30,55,61,73,184]. Endogenous ANO6 expressed in macrophages, or ANO6
overexpressed in HEK293 cells, induced massive membrane blebbing when activated by the
P2X7-agonist ATP [98]. ANO6 also supported apoptosis, movement, and formation of protrusions,
as well as phagocytic activity and bacterial killing by macrophages [98,108]. Importantly,
phosphatidylserine exposure by ANO6 is required for the function of ADAM17 and ADAM10, both
members of the family of cell bound disintegrin and metalloproteases. These enzymes regulate
a plethora of biological functions, including proliferation and cell death [185–187]. The role of
ANO1 for organ development, cell growth and extension of motile cilia and primary cilia has
been discussed above. This is in line with its contribution to exocytosis and release of mucus
or cytokines [107,155,176,188,189]. Moreover, other papers report a function of ANO6 [178] and
ANO1 [190] for the release of microvesicles and exosomes, which could represent a paracrine control
of neighbor cells in airways and intestine [107,191–194]. Notably, ANO1 is excreted in human urinary
exosomes [195]. Interestingly, for both tissue repair [196] and necroptotic cell death [197] a role of
the endosomal-sorting complex required for transport (ESCRT) has been described. Correspondingly,
repair of muscle membrane requires ANO5 [103,198], while ANO6 has a role in necroptotic cell
death [197,199]. Finally, our previous work suggests a role of ANO1, ANO6 and ANO10 in both
membrane swelling and volume regulation by regulatory volume decrease, which is related to
membrane unfolding and phospholipid metabolism [109,176,200] (Figure 5). This will be described in
more detail below.
8. ANO1 Is Upregulated during Inflammation
The current data suggest that upregulated ANO1 in rapidly growing cells and tumors, supports
proliferation, while expression in differentiated non-proliferating cells is generally much lower and
may enable cells to perform specific tasks such as signaling, contraction, or secretion of electrolytes
and mucus. Proliferation and inflammation/hypoxia are intimately connected through multiple
signaling pathways including JACK/STAT [201–203]. Thus, it is not surprising that ANO1 is strongly
upregulated during inflammation, which enabled its molecular identification as CaCC [6,204]. ANO1 is
strongly upregulated in inflammatory airway diseases such as CF, COPD and asthma, which parallels
goblet cell metaplasia and mucus hypersecretion [143,181,205]. It is also upregulated during bacterial
inflammation [206]. Upregulation of TMEM16A is predominant in mucus producing cells and to
a lesser degree in ciliated airway epithelial cells [107,155,205,207]. ANO1 may participate in the
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transition from inflammation to proliferation, which explains its strong impact in wound healing and
tissue repair [14,103,208].
9. Relationship of Anoctamins to the Tumor Associated Cl− Channel VRAC
All living cells are able to maintain a constant cell volume. According to a general concept,
regulatory volume decrease (RVD) prevents cell swelling and necrotic cell death, while regulatory
volume increase (RVI) prevents cell shrinkage and apoptotic cell death [209,210]. The volume regulated
or swelling activated anion channel (VRAC) is activated during RVD. Excessive activation of VRAC
may support apoptotic cell death, while its upregulation leads to cellular resistance towards anti-cancer
drugs [209,211–217]. Recent experiments suggest that ANO1 and ANO6 also contribute to volume
activated whole cell currents, which may indicate a possible functional link between anoctamins and
VRAC [123,176,200,218]. Although broadly expressed, there has been a long controversy concerning
the molecular identity of VRAC, which was finally solved in 2014 [219–221]. Structural analysis by
cryo-EM demonstrated a hexameric assembly of LRRC8 subunits, which form a typical ion channel
with a central pore, structurally related to the connexin family of channels [222–224]. Conserved
charged amino acid residues at the extracellular domain determine the permeability towards anions
and other osmolytes. Two structurally different populations of VRAC have been shown by Kasuya et
al., corresponding to a compact and a relaxed conformation. These conformations may correlate to
closed and open states of the channel [224].
Although rather abundant, LRRC8/VRAC may not be essential for RVD and thus cells may be
able to control their cell volume in the absence of VRAC [225–227]. Lack of functional VRAC leads
to increased prenatal and postnatal mortality, growth retardation, and multiple tissue abnormalities,
including abnormal function of B- and T-cells [228–231]. Additional, LRRC8-independent and
cell-specific mechanisms may exist that enable RVD. These mechanisms comprise other Cl− channels
such CFTR, bestrophin, and anoctamins, as well as electroneutral KCl co-transporter [218,225–227]. An
inverse relationship exists between the magnitudes of VRAC and of Ca2+ activated ANO1 Cl− currents:
With increased activation of CaCC, VRAC decreases and vice versa [232,233]. We could not activate
ANO1 after maximal activation of VRAC [123], while Zholos et al showed a reduced probability for
activation of VRAC after activation of CaCC [233]. A loss of expression of LRRC8A not only inhibited
VRAC, but also attenuated Ca2+ activated Cl− currents. Vice versa, overexpression of LRRC8A
enhanced Ca2+ activated Cl− currents. Because LRRC8A and ANO1 could be co-immunoprecipitated,
a co-localization of both anion channels is proposed, with membrane insertion of LRRC8A being
supported by ANO1 [176]. Apart from ANO1 and ANO6, also VRAC is blocked by niclosamide [95].
Because VRAC induces resistance towards cisplatin and other anticancer drugs and leads to metastasis
and bad patient outcome, inhibition of VRAC may be another mechanism how niclosamide inhibits
growth of cancer [215,234,235].
Taken together, a functional relationship exists between VRAC and ANO1, possibly because
activation of both channels involves release of Ca2+ from the ER-store [200,236]. As VRAC controls
survival of cells, the functional crosstalk with ANO1 is highly relevant for tumor biology [215,234,236].
10. Role of Anoctamins in Cell Death
Sustained large increase in intracellular Ca2+ can lead to senescence or cell death [237,238]. We
showed earlier that P2X7-mediated increase of intracellular Ca2+ leads to cell death of macrophages
and lymphocytes expressing endogenous ANO6, and of HEK293 cells overexpressing ANO6 [98,239].
ANO6 is a component of the so-called outwardly rectifying Cl− channel ORCC or ICOR, and has a role
in cell shrinkage and programmed cell death [218,239–241]. Expression of ANO6 is dominant in the
surface epithelium of large intestine, were aged enterocytes die and dead cells are exfoliated. ANO6 is
not found in intestinal crypts, where enterocytes are produced from stem cells [239]. TUNEL assays
performed in mouse intestinal epithelium lacking ANO6 expression, unmask reduced cell death, when
compared to wt mice. In addition, ANO10 is important for spontaneous and TNFα-induced cell death
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in mouse intestinal epithelium, peritoneal macrophages, and THP1 macrophages [108]. Moreover,
knockdown of ANO6 impaired apoptosis and formation of cyst lumen in 3D cultures of MDCK renal
cysts. ANO6 is normally expressed in apoptotic cells within the center of growing cysts formed by
MDCK cells and human polycystic kidneys [113].
Although many studies demonstrated the pro-proliferative role of ANO1, a pro-apoptotic function
of ANO1 has also been reported [125,242,243]. Almaca et all showed that activation of ANO1 can lead
to apoptotic cell shrinkage [123]. Interestingly, the genes for ANO1 and for apoptosis associated Fas
associated via death domain (FADD), are located on a common amplicon located on chromosome 11q13.
Surprisingly, both proteins were associated with better survival of HNSCC patients [38]. In contrast to
ANO1, which is unable to scramble membrane phospholipids, ANO6-induced cell death is probably
related to its ability to scramble membrane phospholipid [99]. Interestingly, we found that expression
of ANO1 enhanced ionomycin-induced scrambling performed by endogenous ANO6 in HEK293 cells.
This may point to a synergism between both anoctamins, which has also been detected earlier for Cl−
currents produced by both proteins [244].
Meanwhile, a number of independent regulated cell death pathways have been identified [245].
Initially, ANO6 has been reported in the context of apoptosis, but is now shown to be activated
also during necroptosis, pyroptosis and ferroptosis [95,199,246–248]. Thus, activation of anoctamins,
particularly of ANO6, might be a possibility to induce cell death in cancer cells.
11. Activation of Anoctamins and Ferroptotic Cell Death in Cancer
Pro-apoptotic Cl− currents have been activated in cells overexpressing ANO1, ANO6, ANO9 and
ANO10 [95,123,227]. A potent activator of anoctamins is the bee venom melittin, which stimulates
phospholipase A2 (PLA2) [95,200]. Noteworthy, melittin has been widely used as anti-cancer therapy,
and PLA2-dependent activation of metalloproteinase is essential for this effect [249–251].
Anoctamins are also activated through reactive oxygen species and by lipid peroxidation. This
may lead to inflammation and proliferation, ion secretion and ferroptosis, depending on the cell
type, the anoctamin paralogue being activated, and the strength of peroxidation [95,118,247,252,253].
Ferroptosis is induced by accumulation of intracellular iron, and is distinct from apoptosis, necrosis,
and other forms of regulated cell death [254]. Ferroptosis is triggered by an increase in reactive
oxygen species (ROS) and an overwhelming lipid peroxidation that ultimately leads to cell death
by disintegration of the plasma membrane. Experimentally lipid peroxidation is also induced by
erastin-inhibition of cysteine import through the transporter system Xc−. This leads to depletion of
glutathione (GSH) and inactivation of the phospholipid peroxidase glutathione peroxidase 4 (GPX4).
In addition, GPX4 can be directly inhibited by RSL3 [255].
Cell death can be induced in cancer cells by activation of ANO6 through melittin-induced PLA2
or through lipid peroxidation [95]. This may suggest a new potential therapeutic approach to inhibit
growth of cancer [95,247]. Lipid peroxidation and ferroptosis-induced cell death was proposed earlier
as a mechanism to destroy cancer cells [256]. However, the ROS buffer capacity is typically quite high
in cancer cells, which will antagonize lipid peroxidation [257]. ROS levels could be enhanced to exceed
the antioxidant defense of cancer cells [258]. A number of preclinical studies were performed using
small molecules to inhibit cellular glutathione antioxidant activity [259–262]. Tumor cell lines that
were killed by the ANO6-activator melittin were also driven into ferroptosis by erastin and RSL3. Thus
ANO1 and ANO6 were shown to be activated during ferroptotic cell death [118,247].
12. Conclusions
Proteins of the anoctamin/TMEM16 family scramble membrane phospholipids and operate as
Cl− and cation-permeable channels. They demonstrate impressive effects on basic cell properties, and
support both cell proliferation and regulated cell death. Clearly more work is required to be able to
define the cellular functions of anoctamins, and their role in proliferation and cancer development.
Despite the plethora of underlying cell specific signaling pathways, it will be interesting to learn
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whether common mechanisms exist for the cellular effects induced by anoctamins, such as enhanced
intracellular Ca2+ signaling. Blocking ANO1 appears feasible to interfere with cancer growth.
In contrast to the pro-proliferative effect of ANO1, ANO6 seem to contribute to different types of
regulated cell death (Figure 6). Activation of ANO6 may cause swelling or shrinkage of cells, and does
increase in intracellular Ca2+, phospholipid scrambling, membrane blebbing and membrane shedding.
It may all contribute to ANO6-induced cell death. Thus, direct activation of ANO6 may be a promising
new strategy to induce cell death in cancer cells.
Figure 6. ANO6-induced cell death. Scheme summarizing the contribution of ANO6 to different
regulated cell death pathways such as apoptosis, necroptosis, pyroptosis, and ferroptosis. Anoctamins
may contribute to regulated cell death by cell shrinkage (apoptosis), increase in compartmentalized
intracellular Ca2+ (all cell death pathways), or cell swelling, scrambling, blebbing, and membrane
disintegration (ferroptosis, pyroptosis). For further details and references, see main text.
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